Molecular Staging of Malignant Melanoma

Abstract

FOR MOST solid tumors, including colon, lung, and breast carcinoma, the most powerful predictor of patient survival is the status of the regional lymph nodes. Once nodal metastases develop, prognostic factors based on the primary tumor contribute little to the prediction of recurrence and overall survival. For patients with malignant melanoma, the 5-year survival decreases 40% with the development of nodal metastases. Therefore, appropriate emphasis should be placed on accurate nodal staging for melanoma patients.